AETHLON MEDICAL INC 8-K

What Happened

• Aethlon Medical, Inc. announced a 1-for-5 reverse stock split of its common stock by filing a Certificate of Change with the Nevada Secretary of State on July 30, 2026; the split becomes effective July 31, 2026 at 10:00 a.m. ET. Trading on a split-adjusted basis is expected to begin on The Nasdaq Capital Market at the open on August 4, 2026 under the existing symbol “AEMD” and a new CUSIP 00808Y703.
• The company said the reverse split is part of its capital-markets and operating plan, including dilution management and continued compliance with Nasdaq Listing Rule 5550(a)(2).

Key Details

• Reverse ratio: 1-for-5; effective July 31, 2026 (filing made July 30, 2026).
• Outstanding shares: 3,249,569 pre-split (as of July 23, 2026) → approximately 649,914 post-split (subject to rounding).
• Authorized common shares reduced from 100,000,000 to 20,000,000; authorized preferred shares unchanged.
• Fractional shares: no fractional shares will be issued; the company will issue one whole post-split share to any stockholder who otherwise would have received a fractional share. Computershare Transfer, Inc. is the transfer and exchange agent. Registered and brokerage account holders need take no action.

Why It Matters

• For investors, the reverse split reduces the number of outstanding shares and increases the per-share price proportionally, but does not materially change any stockholder’s percentage ownership or voting power (except for minor rounding effects).
• The move is intended to help Aethlon remain compliant with Nasdaq listing rules and potentially improve the company’s capital-markets profile; holders should note the new CUSIP and expected split-adjusted trading date.
• All options, warrants and convertible securities will be adjusted to reflect the reverse split.